Amgen (AMGN) Debt Ratio (2009 - 2026)
Amgen's quarterly Debt Ratio came in at 0.62 in Q1 2026, down 3.49% year-on-year from 0.64 in Q1 2025, and up 2.8% quarter-over-quarter from 0.6 in Q4 2025.
Amgen has reported Debt Ratio for 18 years, with the latest figure at 0.62 in Q1 2026.
- For the quarter ending Q1 2026, Debt Ratio fell 3.49% year-over-year to 0.62; the trailing twelve-month figure through Mar 2026 stood at 0.62 (down 3.49% YoY), and the FY2025 full-year result was 0.6, down 7.89% from the prior year.
- Debt Ratio for Q1 2026 stood at 0.62, up from 0.6 in the prior quarter.
- The five-year high for Debt Ratio was 0.69 in Q1 2023, with the low at 0.6 in Q4 2022.
- Average Debt Ratio over 5 years is 0.64, with a median of 0.64 recorded in 2025.
- Year-over-year, Debt Ratio increased 19.12% in 2022 and retreated 8.88% in 2025.
- Tracing AMGN's Debt Ratio over 5 years: stood at 0.6 in 2022, then gained by 11.21% to 0.67 in 2023, then decreased by 1.6% to 0.65 in 2024, then retreated by 7.89% to 0.6 in 2025, then grew by 2.8% to 0.62 in 2026.
- The last three Debt Ratio figures came in at 0.62 (Q1 2026), 0.6 (Q4 2025), and 0.61 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 0.37 |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 0.27 |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 0.47 |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 0.38 |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 0.62 |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 0.39 |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 0.31 |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 0.51 |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | 0.29 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.62 |
| Dec 31, 2025 | 0.60 |
| Sep 30, 2025 | 0.61 |
| Jun 30, 2025 | 0.64 |
| Mar 31, 2025 | 0.64 |
| Dec 31, 2024 | 0.65 |
| Sep 30, 2024 | 0.66 |
| Jun 30, 2024 | 0.69 |
| Mar 31, 2024 | 0.69 |
| Dec 31, 2023 | 0.67 |
| Sep 30, 2023 | 0.67 |
| Jun 30, 2023 | 0.68 |
| Mar 31, 2023 | 0.69 |
| Dec 31, 2022 | 0.60 |
| Sep 30, 2022 | 0.61 |
| Jun 30, 2022 | 0.62 |
| Mar 31, 2022 | 0.62 |
| Dec 31, 2021 | 0.54 |
| Sep 30, 2021 | 0.58 |
| Jun 30, 2021 | 0.55 |
| Mar 31, 2021 | 0.52 |
| Dec 31, 2020 | 0.52 |
| Sep 30, 2020 | 0.53 |
| Jun 30, 2020 | 0.53 |
| Mar 31, 2020 | 0.52 |
| Dec 31, 2019 | 0.50 |
| Sep 30, 2019 | 0.50 |
| Jun 30, 2019 | 0.52 |
| Mar 31, 2019 | 0.52 |
| Dec 31, 2018 | 0.51 |
| Sep 30, 2018 | 0.51 |
| Jun 30, 2018 | 0.51 |
| Mar 31, 2018 | 0.50 |
| Dec 31, 2017 | 0.44 |
| Sep 30, 2017 | 0.45 |
| Jun 30, 2017 | 0.44 |
| Mar 31, 2017 | 0.44 |
| Dec 31, 2016 | 0.45 |
| Sep 30, 2016 | 0.45 |
| Jun 30, 2016 | 0.44 |
| Mar 31, 2016 | 0.46 |
| Dec 31, 2015 | 0.44 |
| Sep 30, 2015 | 0.44 |
| Jun 30, 2015 | 0.45 |
| Mar 31, 2015 | 0.44 |
| Dec 31, 2014 | 0.45 |
| Sep 30, 2014 | 0.47 |
| Jun 30, 2014 | 0.48 |
| Mar 31, 2014 | 0.44 |
| Dec 31, 2013 | 0.49 |
| Sep 30, 2013 | 0.48 |
| Jun 30, 2013 | 0.45 |
| Mar 31, 2013 | 0.46 |
| Dec 31, 2012 | 0.44 |
| Sep 30, 2012 | 0.43 |
| Dec 31, 2011 | 0.44 |
| Mar 31, 2010 | 0.23 |
| Dec 31, 2009 | 0.15 |
| Sep 30, 2009 | 0.15 |
| Jun 30, 2009 | 0.16 |